December 28, 2025 a 01:00 pm
BSX: Analysts Ratings - Boston Scientific Corporation
Boston Scientific Corporation, a prominent player in the medical device industry, continues to maintain a strong market position with its diversified portfolio. Analysts are optimistic about the company's growth prospects, as indicated by a high number of "Buy" and "Strong Buy" recommendations. The company's innovative approach and strategic investments contribute to the positive sentiment in the market.
Historical Stock Grades
The pattern in analyst ratings for Boston Scientific Corporation highlights ongoing confidence in the company's performance. The stable and high number of Buy and Strong Buy ratings is a testament to the company's robust market positioning.
| Rating Type | Count | Score |
|---|---|---|
| Strong Buy | 7 | |
| Buy | 25 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
- The current sentiment remains predominantly positive, with the majority of analysts recommending Buy or Strong Buy.
- The overall number of ratings has been stable, suggesting a consensus on the company's strong performance.
- The Hold ratings have slightly decreased, indicating increased analyst confidence in the firm's prospects.
- No Sell or Strong Sell ratings were issued, marking a strong sentiment towards the company's market activities.
Percentage Trends
- There has been a slight shift from Strong Buy to Buy, indicating slight caution amid an overall optimistic outlook.
- In recent months, the percentage of Hold ratings has slightly decreased, aligning with the general favorable outlook.
- The absence of Sell and Strong Sell ratings shows resilient confidence in Boston Scientific Corporation's strategy.
- A notable increase in Buy recommendations suggests growing trust in the company's growth trajectory and financial health.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-18 | Buy | Buy | Truist Securities |
| 2025-12-17 | Outperform | Outperform | RBC Capital |
| 2025-12-17 | Buy | Buy | Canaccord Genuity |
| 2025-11-21 | Buy | Buy | BTIG |
| 2025-10-23 | Overweight | Overweight | Wells Fargo |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-09-08 | Outperform | Perform | Oppenheimer |
| 2025-04-16 | Buy | Hold | Needham |
| 2024-10-18 | Hold | Buy | Needham |
| 2024-02-01 | Buy | Neutral | Mizuho |
| 2022-05-27 | Buy | Hold | Needham |
Interpretation
The analyst ratings for Boston Scientific Corporation reflect a prevailing confidence in the company's ability to sustain its market leadership. The consistency in Buy and Strong Buy recommendations suggests minimal uncertainty. The absence of downturn ratings over an extended period points to investor and analyst trust in the company's strategic direction and financial stability.
Conclusion
Boston Scientific Corporation remains a strong contender in the medical device sector with consistent analyst support. The stable trend in ratings with an emphasis on Buy recommendations underscores the market's positive outlook. Analysts appear assured in the company's ability to innovate and expand, although slight caution noted from adjustments between Buy and Strong Buy should be monitored. Such dynamics highlight both growth potential and the subtle risk of overvaluation in an otherwise optimistic scenario.